Teva Canada Announces the Launch of AJOVY™ For the Preventive Treatment of Migraine in Adults Who Have at Least Four Migraine Days Per Month
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Business Wire
AJOVY™ is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults AJOVY™ has been studied in patients with chronic or episodic migraine and was shown to significantly reduce patients’ mean monthly migraine days—with some patients achieving a 50% reduction or more.1–3Migraine is a prevalent neurological disorder, affecting more than 760,000 people in Canada and 1 billion worldwide.4,5 MONTRÉAL--(BUSINESS WIRE)--Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has recently granted a notice of compliance (NOC) to AJOVY™ (fremanezumab) 225 mg solution for subcutaneous injection in a pre-filled syringe for the preventive treatment of migraine in adults who have at least four migraine days per month. AJOVY™ is a humanized monoclonal antibody (mAb) that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. AJOVY™ is the
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of MedicineGlobeNewswire
- Is It Too Late To Reassess Teva (TEVA) After A 55% One Year Rally? [Yahoo! Finance]Yahoo! Finance
- Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues [Yahoo! Finance]Yahoo! Finance
- Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation [Yahoo! Finance]Yahoo! Finance
- Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through InnovationGlobeNewswire
TEVA
Earnings
- 11/5/25 - Beat
TEVA
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- TEVA's page on the SEC website